Literature DB >> 17513698

Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study.

Hussam Al-Kateb1, Lucia Mirea, Xinlei Xie, Lei Sun, Michelle Liu, Hongtao Chen, Shelley B Bull, Andrew P Boright, Andrew D Paterson.   

Abstract

OBJECTIVE: We sought to determine if any common variants in the gene for vascular endothelial growth factor (VEGFA) are associated with long-term renal and retinal complications in type 1 diabetes. RESEARCH DESIGN AND METHODS: A total of 1,369 Caucasian subjects with type 1 diabetes from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study had an average of 17 retinal photographs and 10 renal measures over 15 years. In the DCCT/EDIC, we studied 18 single nucleotide polymorphisms (SNPs) in VEGFA that represent all linkage disequilibrium bins (pairwise r(2) > or = 0.64) and tested them for association with time to development of severe retinopathy, three or more step progression of retinopathy, clinically significant macular edema, persistent microalbuminuria, and severe nephropathy.
RESULTS: In a global multi-SNP test, there was a highly significant association of VEGFA SNPs with severe retinopathy (P = 6.8 x 10(-5))-the four other outcomes were all nonsignificant. In survival analyses controlling for covariate risk factors, eight SNPs showed significant association with severe retinopathy (P < 0.05). The most significant single SNP association was rs3025021 (hazard ratio 1.37 [95% CI 1.13-1.66], P = 0.0017). Family-based analyses of severe retinopathy provide evidence of excess transmission of C at rs699947 (P = 0.029), T at rs3025021 (P = 0.013), and the C-T haplotype from both SNPs (P = 0.035). Multi-SNP regression analysis including 15 SNPs, and allowing for pairwise interactions, independently selected 6 significant SNPs (P < 0.05).
CONCLUSIONS: These data demonstrate that multiple VEGFA variants are associated with the development of severe retinopathy in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17513698     DOI: 10.2337/db07-0376

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  40 in total

1.  Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population.

Authors:  Roberto Gonzalez-Salinas; Maria C Garcia-Gutierrez; Gerardo Garcia-Aguirre; Virgilio Morales-Canton; Raul Velez-Montoya; Vidal R Soberon-Ventura; Victoria Gonzalez; Rodrigo Lechuga; Pablo Garcia-Solis; David G Garcia-Gutierrez; Marco Vinicio Garcia-Solis; Manuel Saenz de Viteri; Juan C Solis-S
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

Review 2.  The role of genetics in susceptibility to diabetic retinopathy.

Authors:  Gerald Liew; Ronald Klein; Tien Y Wong
Journal:  Int Ophthalmol Clin       Date:  2009

3.  Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach.

Authors:  Zhen-zhong Yang; Wei Liu; Feng Zhang; Zheng Li; Yi-yu Cheng
Journal:  Acta Pharmacol Sin       Date:  2015-05-11       Impact factor: 6.150

4.  Genome-wide meta-analysis for severe diabetic retinopathy.

Authors:  Michael A Grassi; Anna Tikhomirov; Sudha Ramalingam; Jennifer E Below; Nancy J Cox; Dan L Nicolae
Journal:  Hum Mol Genet       Date:  2011-03-26       Impact factor: 6.150

5.  Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study.

Authors:  Catherine Kim; Carrie Karvonen-Gutierrez; Shengchun Kong; Valerie Arends; Michael Steffes; Daniel S McConnell; John F Randolph; Siobán D Harlow
Journal:  Fertil Steril       Date:  2016-07-28       Impact factor: 7.329

6.  Polymorphisms of VEGFA gene and susceptibility to hemorrhage risk of brain arteriovenous malformations in a Chinese population.

Authors:  Zhi-ping Gong; Ni-dan Qiao; Yu-xiang Gu; Jian-ping Song; Pei-liang Li; Hui-jia Qiu; Wei-wei Fan; Ying Mao; Hong-yan Chen; Yao Zhao
Journal:  Acta Pharmacol Sin       Date:  2011-06-27       Impact factor: 6.150

Review 7.  Vascular endothelial growth factor and diabetic nephropathy.

Authors:  Sheldon Chen; Fuad N Ziyadeh
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

8.  Association of vascular endothelial growth factor expression and polymorphisms with the risk of gestational diabetes mellitus.

Authors:  Ping-Ping Dong
Journal:  J Clin Lab Anal       Date:  2018-10-23       Impact factor: 2.352

9.  Lipid and endothelium-related genes, ambient particulate matter, and heart rate variability--the VA Normative Aging Study.

Authors:  C Ren; A Baccarelli; E Wilker; H Suh; D Sparrow; P Vokonas; R Wright; J Schwartz
Journal:  J Epidemiol Community Health       Date:  2010-01       Impact factor: 3.710

10.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.